4 results about "Neo angiogenesis" patented technology

The application discloses a dual-specific antibody with functions of inflammation microenvironment regulation and simultaneous inhibition of choroidal neovascularization, and a preparation method and application thereof. The dual-specific antibody is a single-chain antibody, comprises an IL1R, an IL-1 receptor complex auxiliary subunit IL-1RAcP fragment, and extracellular domains D2 (VEGFR2D2) and D3 (VEGFR2D3) of a tyrosine kinase transmembrane receptor VEGFR2, can simultaneously bind to IL-1 and VEGF, has functions of regulating an inflammation microenvironment and inhibiting choroidal neovascularization, and can more accurately treat fundus-related diseases represented by age-related macular degeneration.

The invention discloses an application of an FAP targeting drug and an anti-PD-1 antibody in combined treatment of colorectal cancer. The invention proves that the combined application of PT-100 and anti-PD-1 therapy shows good effects in the aspects of inhibiting colorectal cancer tumor growth, prolonging the survival time of mice, enhancing tumor cell apoptosis, inhibiting angiogenesis and remodeling tumor immune microenvironment by regulating immune cell subpopulation, and has acceptable tolerance. The invention provides a new treatment strategy and pharmaceutical composition for treatment of colorectal cancer, is expected to overcome the drug resistance of colorectal cancer immunotherapy, and also provides a theoretical basis for clinical transformation of combined application of an FAP strategy and immune checkpoint blocking.

The invention provides application of an NCOA3 polyQ structural domain in preparation of a medicine for relieving ocular vascular abnormal hyperplasia diseases, relates to the technical field of biomedicine, and aims to solve the problems that in the prior art, an ocular pathological angiogenesis mechanism is complex, and safe and effective targeted intervention means are lacked. The construction of a mouse corneal micropocket pathological angiogenesis model proves that Nco3polyQ structural domain deletion can significantly inhibit corneal neovascularization: compared with a WT mouse, the Nco3wt / Q mouse corneal tissue CD31 positive signal is reduced, the number of corneal neovascularization in the Nco3Q / Q mouse is minimum, and the CD31 positive area is minimum; meanwhile, qPCR (quantitative polymerase chain reaction) detection of corneal tissues shows that mRNA (messenger ribonucleic acid) expression of the vascular marker genes Pecam1 and Cdh5 is in a decreasing trend and is further decreased in an Nco3Q / Q mouse. On the basis, the intervention strategy aiming at the NCOA3 polyQ structural domain is used for preparing the medicine for relieving the abnormal hyperplasia diseases of the ocular blood vessels, and a new treatment strategy and a potential target are provided for related diseases of the ophthalmology department.

The invention provides a preparation capable of inhibiting tumor angiogenesis, and belongs to the technical field of tumor angiogenesis inhibition. The preparation provided by the invention contains an inhibitor capable of obviously knocking out expression of VEGF, the inhibitor is siRNA, the siRNA is utilized to silence VEGF-mRNA, the silence efficiency is as high as 90%, the expression level of VEGF protein in HepG2 cells is effectively reduced, tumor angiogenesis can be better targeted, and tumor angiogenesis can be effectively inhibited. Therefore, the compound can be used for preparing a preparation with the effect of inhibiting tumor angiogenesis.